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Heart disease, stroke and renal failure are leading causes of death with hypertension 
being the predominant risk factor (1,2). Extensive evidence from randomized 
controlled trials has clearly demonstrated benefit of antihypertensive treatment and 
blood pressure reduction in reducing cardiovascular events in individuals with 
hypertension (3-5). Accordingly effective blood pressure control is essential to 
prevent the adverse sequelae of hypertension. While modern drugs have the capacity 
to reduce blood pressure in almost every patient with hypertension (6,7), the actual 
blood pressure thresholds at which treatment should be initiated and the target levels 
at which blood pressure should be maintained still remain a topic of much discussion 
and debate. 
To inform health care providers and to provide pragmatic clinical suggestions and 
recommendations, international, regional and national hypertension guidelines have 
been developed by expert groups globally. Most major hypertension treatment 
guidelines currently suggest that clinicians should strive to treat adults to a  blood 
pressure target of d140/90 mmHg (8-14). Regarding goals for older individuals, a 
2014 report from panel members of the eighth joint national committee (JNC8) 
suggested that in persons aged 60 years or older blood pressure should be targeted to 
less than 150/90 mmHg (12). The French guidelines recommend that individuals 80 
years or older should be treated to a target of 150/90 mmHg (15), while the Canadian 
guidelines suggest that in the very elderly (e   80 years) the threshold for initiating 
drug treatment should be 160 mmHg (14).  
Hypertension guidelines, in large part, are evidence-based and are usually dictated by 
randomized controlled trial data and observational studies. While there is general 
consensus between major guidelines that treatment should aim at lowering blood 
pressure in adults to 140/90 mmHg (8-14), what has been less clear is whether there is 
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further cardiovascular benefit when blood pressure is treated more intensively to a 
goal lower than 140/90 mmHg.  
Exactly how low blood pressure should be targeted remains a matter of intense 
discussion. This is highlighted by the many studies that have demonstrated that below 
a certain level of blood pressure, more aggressive reductions may not be associated 
with benefit and actually increase the risk of harm. The notion of the ‘J-curve’ defined 
as the occurrence of additional cardiovascular events when the blood pressure is 
lowered beyond the level required to maintain tissue perfusion, refers primarily to 
diastolic blood pressure (16,17). Exactly what the critical diastolic blood pressure is, 
particularly in the population at large, is still unclear but treatment to a level below 
65mmHg has been suggested to be associated with additional harm (16-18). Current 
guidelines suggest treatment targets for diastolic blood pressure below 90 mmHg, 
which seems ‘safe’ in the J-curve phenomenon.  
But what about systolic blood pressure? Is there a J-curve for systolic blood pressure 
and is 140 mmHg truly the level associated with maximum benefit? Despite 
guidelines suggesting this, until recently, there was little evidence that lower systolic 
blood pressure targets may have greater cardiovascular protection. However, three 
recent important studies, SPRINT (19) and two large meta-analyses clearly showed 
that lower systolic blood pressures may indeed be better (20,21). The main finding in 
SPRINT was that a primary composite outcome of cardiovascular disease and death 
was reduced by 25% and all-cause mortality by 27% in patients treated intensively to 
a systolic blood pressure target of <120 mmHg (19). However, it should be stressed 
that SPRINT was restricted to hypertensive adults, including the eldery (> 75 years), 
at above-average risk of cardiovascular disease and that diabetic patients and those 
who had already had a stroke, were excluded (12). Xie et al (20), in a meta-analysis of 
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over 44,000 patients, showed that intensive blood pressure lowering below 140 
mmHg was associated with improved cardiovascular and renal outcomes. Ettehad et 
al (21) reported in a systematic review and meta-analysis of over 613,000 participants 
that lowering blood pressure to a systolic blood pressure of less than 130 mmHg 
significantly reduced cardiovascular events and mortality.  
While these recent meta-analyses, together with the SPRINT findings, are highly 
suggestive that there is increased benefit when patients with hypertension are treated 
to systolic blood pressures below the currently suggested target of 140 mmHg, there 
are some important aspects of these studies that should be highlighted. In particular, 
the meta-analyses comprised trials with heterogeneous cohorts and thus identifying 
those individuals who would benefit most from intensive treatment to lower blood 
pressure targets is difficult. In addition, in all three studies, the focus of intensive 
therapy was on systolic blood pressure and it remains unclear whether a concomitant 
reduction in diastolic blood pressure (which is likely with intensive anti-hypertensive 
treatment), would also result in a reduced rate of cardiovascular events. Not with 
standing some of these issues the potential impact of SPRINT and the recent meta-
analyses, on diagnosing, treating and managing patients with hypertension is 
immense, not only from the health-care and patients well-being point of view, but also 
from the societal and health economic position. It is likely that these studies will lead 
to changes in clinical practice. Accordingly, it is now timely to re-think blood 
pressure thresholds and targets. As hypertension experts we have the responsibility to 
re-evaluate current evidence and re-appraise guidelines for diagnosis and 
management. Exactly what the future recommendations will be remain uncertain, 
because the data from the recent studies (19-21) still need to be digested and further 
analysed in the context of current evidence-based studies, but it is very likely that 
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there will be a strong move towards more aggressive control of hypertension to lower 
blood pressure targets. With the awaited new ACC/AHA guidelines soon to be 
finalized, re-assessment of existing guidelines and more SPRINT sub-studies to be 
published, the landscape of diagnosing and treating hypertension may change 
significantly in the near future.  
Over the next few months, we will seek opinions and comments from key leaders 
involved in regional and international hypertension guidelines. As such we will 
provide views from across the world regarding the potential impact of the new 
findings of lower systolic blood pressure targets and future guidelines. Through this 
platform, ‘Hypertension’, as the premier journal in the field, will serve the 
hypertension community by keeping readers abreast of how the new land-mark 
studies will influence major guidelines and decision-making for best practice. 
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